M. Labéta

发表

Prevention of experimental endotoxin shock by a monocyte activator

J. Izbicki, U. Pichlmeier, B. Passlick, 1995, Antimicrobial Agents and Chemotherapy.

Disrupting TLR2 Triggering Compromising Bacterial Clearance by Soluble TLR2 Reduces Inflammation without

Simon A. Jones, P. Brennan, M. Labéta, 2009 .

Soluble TLR2 Reduces Inflammation without Compromising Bacterial Clearance by Disrupting TLR2 Triggering1

Simon A. Jones, P. Brennan, M. Labéta, 2009, The Journal of Immunology.

Modulation of Neonatal Microbial Recognition: TLR-Mediated Innate Immune Responses Are Specifically and Differentially Modulated by Human Milk1

Michael Affolter, M. Affolter, M. Labéta, 2006, The Journal of Immunology.

Solubilisation effect of Nonidet P-40, triton X-100 and CHAPS in the detection of MHC-like glycoproteins.

M. Labéta, N. Fernandez, H. Festenstein, 1988, Journal of immunological methods.

CD14 and tolerance to lipopolysaccharide: biochemical and functional analysis.

R. Herrmann, J. Durieux, M. Labéta, 1993, Immunology.

Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors

C. Fielding, Simon A. Jones, M. Labéta, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Innate Recognition of Bacteria in Human Milk Is Mediated by a Milk-Derived Highly Expressed Pattern Recognition Receptor, Soluble Cd14

M. Affolter, P. Ferrara, M. Labéta, 2000, The Journal of experimental medicine.

Major histocompatibility complex (MHC) protein analysis by optimised two‐dimensional electrophoretic methods

M. Labéta, N. Fernández, T. Nakatsuji, 1990, Electrophoresis.

Down-regulation of surface monocyte lipopolysaccharide-receptor CD14 in patients on cardiopulmonary bypass undergoing aorta-coronary bypass operation.

G. Fingerle-Rowson, M. Labéta, M. Blumenstein, 1998, The Journal of thoracic and cardiovascular surgery.

The two soluble forms of the lipopolysaccharide receptor, CD14: Characterization and release by normal human monocytes

P. Ferrara, J. Durieux, M. Labéta, 1994, European journal of immunology.

Evidence of expression of endotoxin receptors CD14, toll‐like receptors TLR4 and TLR2 and associated molecule MD‐2 and of sensitivity to endotoxin (LPS) in islet beta cells

R. Gomis, M. Labéta, R. Pujol-Borrell, 2003, Clinical and experimental immunology.

Biochemical analysis of a novel H-2 class I-like glycoprotein expressed in five AKR-(Gross virus) derived spontaneous T cell leukemias.

P. Ferrara, M. Labéta, N. Fernández, 1989, Journal of Immunology.

Serological biochemical and functional characterisation of three different HLA-DR monoclonal antibodies derived from C57BL6 mice.

M. Labéta, N. Fernandez, H. Festenstein, 2008, Tissue antigens.

Complement takes its Toll: an inflammatory crosstalk between Toll‐like receptors and the receptors for the complement anaphylatoxin C5a

M. Labéta, J. Hall, A. Raby, 2012, Anaesthesia.

Present in Human Plasma and Breast Milk Capable of Modulating TLR2 Signaling Are Soluble Forms of Toll-Like Receptor (TLR)2

M. Grigorov, S. Lawn, M. Affolter, 2003 .

Soluble CD14 in human breast milk and its role in innate immune responses

M. Labéta, E. Schiffrin, A. Donnet-Hughes, 2001, Acta odontologica Scandinavica.

The lipopolysaccharide co‐receptor CD14 is present and functional in seminal plasma and expressed on spermatozoa

M. Labéta, B. Morgan, C. Harris, 2001, Immunology.

Release from a human monocyte‐like cell line of two different soluble forms of the lipopolysaccharide receptor, CD14

P. Ferrara, R. Herrmann, J. Durieux, 1993, European journal of immunology.

Soluble CD14 acts as a negative regulator of human T cell activation and function

P. Ferrara, Matthew Jones, M. Labéta, 1999, European Journal of Immunology.

Cutting Edge: Human B Cell Function Is Regulated by Interaction with Soluble CD14: Opposite Effects on IgG1 and IgE Production1

P. Ferrara, M. Labéta, L. Borysiewicz, 2000, The Journal of Immunology.

Human B cells express membrane-bound and soluble forms of the CD14 myeloid antigen.

R. Landmann, M. Labéta, J. Obrecht, 1991, Molecular immunology.

A novel HLA class II molecule

M. Labéta, N. Fernández, H. Festenstein, 2004, Immunogenetics.

A Novel HLA-Class II Molecule Distinct from HLA-DP/DQ/DR

M. Labéta, N. Fernández, H. Festenstein, 1989 .

Preventing Peritoneal Dialysis-Associated Fibrosis by Therapeutic Blunting of Peritoneal Toll-Like Receptor Activity

M. Labéta, A. Raby, 2018, Front. Physiol..

Targeting Toll-like receptors with soluble Toll-like receptor 2 prevents peritoneal dialysis solution-induced fibrosis.

M. Labéta, N. Topley, D. Fraser, 2018, Kidney international.

Elevated serum concentrations of soluble CD14 in HIV− and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti‐tuberculosis treatment

S. Lawn, M. Labéta, J. Acheampong, 2000, Clinical and experimental immunology.

Soluble Toll-like receptor 2 is a biomarker for sepsis in critically ill patients with multi-organ failure within 12 h of ICU admission

Judith E. Hall, T. Szakmany, M. Labéta, 2017, Intensive Care Medicine Experimental.

Cell-surface expression of human histocompatibility leucocyte antigen (HLA) class II-associated invariant chain (CD74) does not always correlate with cell-surface expression of HLA class II molecules.

G. Pawelec, M. Labéta, N. Fernández, 1993, Immunology.

mSep: investigating physiological and immune-metabolic biomarkers in septic and healthy pregnant women to predict feto-maternal immune health – a prospective observational cohort study protocol

S. Edkins, N. Angelopoulos, J. McLaren, 2022, BMJ Open.

The Antibody MY4 Recognizes CD14 on Porcine Monocytes and Macrophages

J. Izbicki, B. Passlick, M. Labéta, 1994, Scandinavian journal of immunology.

Analytical studies of the binding parameters describing the interaction of HLA-DR epitopes with a specific monomorphic monoclonal antibody.

M. Labéta, N. Fernandez, H. Festenstein, 1987, Journal of immunological methods.

FUNCTIONAL STUDIES OF H‐2k‐LIKE EPITOPES ON DTIC TREATED AND UNTREATED L1210 (H‐2d) CLONES

M. Labéta, H. Festenstein, O. Marelli, 1989, Journal of immunogenetics.

Structure of asymmetric non-precipitating antibody: presence of a carbohydrate residue in only one Fab region of the molecule.

J. Leoni, M. Labéta, R. Binaghi, 1986, Immunology.

The asymmetric IgG non-precipitating antibody. Localization of the oligosaccharide involved, by concanavalin A interaction.

J. Leoni, M. Labéta, R. Margni, 1986, Molecular immunology.

MHC Antigen Expression in Malignant Tumours and Their Effects on Host-Tumour Interaction

M. Labéta, H. Festenstein, 1987 .

Targeting the TLR Co-Receptor CD14 with TLR2-Derived Peptides Modulates Immune Responses to Pathogens

Judith E. Hall, P. Ferrara, T. Szakmany, 2013, Science Translational Medicine.

Soluble Forms of Toll-Like Receptor (TLR)2 Capable of Modulating TLR2 Signaling Are Present in Human Plasma and Breast Milk

M. Grigorov, S. Lawn, M. Affolter, 2003, The Journal of Immunology.

THE EXPRESSION OF MURINE Qa REGION GENE PRODUCT(S) IN L CELL TRANSFORMANTS

P. A. Biro, R. Flavell, E. Carolan, 1986, Journal of immunogenetics.

TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2

J. Köhl, M. Labéta, B. Morgan, 2011, European journal of immunology.

Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis.

M. Eberl, J. Köhl, M. Labéta, 2017, Journal of the American Society of Nephrology : JASN.

Detection and biochemical characteristics of the receptor for complexes of soluble CD14 and bacterial lipopolysaccharide.

P. Ferrara, M. Labéta, L. Borysiewicz, 1997, Journal of immunology.

Therapeutic Boosting of the Immune Response: Turning to CD14 for Help

M. Labéta, A. Raby, 2016, Current pharmaceutical biotechnology.

Preventing Peritoneal Dialysis-Associated Fibrosis by Therapeutic Blunting of Peritoneal Toll-Like Receptor Activity

M. Labéta, A. Raby, 2018, Front. Physiol..

Soluble CD14 acts as a negative regulator of human T cell activation and function

P. Ferrara, Matthew Jones, M. Labéta, 1999, European journal of immunology.

A ligand-epitope in vitro analysis of major histocompatibility determinants expressed on B and T lymphocytes.

G. Pawelec, M. Labéta, N. Fernández, 1992, Immunology.

Therapeutic targeting of chronic kidney disease-associated DAMPs differentially contributing to vascular pathology

D. Ramji, M. Labéta, N. Ipseiz, 2023, Frontiers in immunology.

Calprotectin blockade inhibits long-term vascular pathology following peritoneal dialysis-associated bacterial infection

M. Labéta, G. Gónzalez-Mateo, A. Raby, 2023, Frontiers in cellular and infection microbiology.